IMTX: Immatics Corp Net earnings per share (EPS TTM)

Immatics (IMTX) - corporate logo

Geopolitical fragmentation and logistical disruptions are limiting the global tests of Immatics N.V. (IMTX). Analyzing the chart on GURU.Markets, we find that net income per share over the last four quarters has remained around -1.96. Immatics N.V. (IMTX) relies on a diversified portfolio of T-cell targets, mitigating risks through partnerships. High R&D expenses are scaled jointly with pharma behemoths until the drugs reach commercial launch.

IMTX Immatics N.V. Net earnings per share for the last 12 months (07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for Immatics Biotechnologies (IMTX)

- share price and expert price forecast:
Stock Quotes Immatics|IMTX - Fair Value Consensus
- market capitalization information:
Market Capitalization Immatics|IMTX - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Immatics|IMTX - Company Net Assets|Market Value to Book Value Ratio immatics.com|IMTX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Immatics N.V.|IMTX - Long-Term Debt to Capital|Short-Term Debt to Equity Immatics|IMTX - Company Aggregate Debt|Debt to Book Capitalization Ratio Immatics N.V.|IMTX - Long-Term Debt|Company Current Liabilities Immatics|Quick Liquidity Indicator immatics.com
- earnings and multiples data:
IMTX - Profit After Payment of Taxes|Projected Future Earnings Immatics N.V.|IMTX - Company Value to Net Income|Forward P/E Multiple immatics.com|IMTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immatics Biotechnologies|IMTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Immatics|IMTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months immatics.com|IMTX - Earnings per share trend in current year|Expected earnings per share growth for next year Immatics N.V.
- revenue and sales details:
IMTX - Company Total Revenue|Projected Sales Volume Immatics NV|IMTX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Immatics Biotechnologies
Fundamental valuation:IMTX - Immatics Biotechnologies
Flagship merchandise of Immatics Corp

Finding a balance between operational risks and return on capital at Immatics N.V. (IMTX) requires an analysis of the effectiveness of cancer immunotherapy development and advances from pharmaceutical partners. The 12-month net income per share trend reflects the bottom line adjusted for the volume of issuance, allowing for an assessment of the real yield of each security and the sustainability of the company's business model during periods of asset revaluation.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)